NCT02579239View on ClinicalTrials.gov

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 5, 2016

Study Completion Date

October 5, 2016

Conditions
Limb-Girdle Muscular DystrophiesFacioscapulohumeral Muscular Dystrophy
Interventions
BIOLOGICAL

ATYR1940

Concentrate for solution for infusion

BIOLOGICAL

Placebo

Concentrate for solution for infusion

Trial Locations (6)

13385

Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET), Marseille

21205

Kennedy Krieger Institute; The Johns Hopkins University School of Medicine, Baltimore

43210

OSU Wexner Medical Center, Columbus

92697

University of California, Irvine, ALS and Neuromuscular Center, Irvine

Unknown

Rigshospitalet, University of Copenhagen, Copenhagen

Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

aTyr Pharma, Inc.

INDUSTRY

NCT02579239 - Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) | Biotech Hunter | Biotech Hunter